^[1] Ghany MG et al. Diagnosis, management, and treatment of hepatitis C: an update. American Association for the Study of Liver Diseases. Hepatology. 2009 Apr;49(4):1335–74
^[2] Armstrong GL et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006 May 16;144(10):705–14
^[3] Bartenschlager R. The hepatitis C virus replicon system: from basic research to clinical application. J Hepatol. 2005 Aug;43(2):210–6
^[4] Guideline der American Association for the Study of Liver Diseases www.hcvguidelines.org/ Zugriff 1.9.2016
^[5] Hüppe D et a. Epidemiology of chronic hepatitis C in Germany – an analysis of 10.326 patients in hepatitis centres and outpatient units. Z Gastroenterol. 2008 Jan;46(1):34–44
^[6] European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015 Jul;63(1):199–236
^[7] Stahmeyer JT et al. Costs of a guideline-based treatment of patients with chronic hepatitis C in the era of interferon-free treatment. Z Gastroenterol. 2016 Aug;54(8):760–9
^[8] Mauss S et al. Real-life experience with first generation HCV protease inhibitor therapy in Germany: The prospective, non-interventional PAN cohort. Z Gastroenterol. 2015 Jul;53(7):644–54
^[9] WHO. Guidelines for the screening, care and treatment of persons with chronic Hepatitis C infection; updated version April 2016.